Your browser is no longer supported. Please, upgrade your browser.
Settings
DARE Dare Bioscience, Inc. daily Stock Chart
DARE [NASD]
Dare Bioscience, Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own18.95% Shs Outstand15.99M Perf Week-11.17%
Market Cap22.07M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float13.52M Perf Month64.40%
Income-14.10M PEG- EPS next Q-0.17 Inst Own4.80% Short Float4.80% Perf Quarter60.09%
Sales- P/S- EPS this Y56.20% Inst Trans- Short Ratio0.42 Perf Half Y84.00%
Book/sh0.11 P/B12.55 EPS next Y25.30% ROA-235.20% Target Price4.00 Perf Year66.04%
Cash/sh0.15 P/C9.19 EPS next 5Y- ROE-324.20% 52W Range0.69 - 3.25 Perf YTD68.29%
Dividend- P/FCF- EPS past 5Y33.50% ROI- 52W High-57.54% Beta2.21
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin- 52W Low99.94% ATR0.18
Employees19 Current Ratio1.70 Sales Q/Q- Oper. Margin- RSI (14)58.98 Volatility8.87% 10.32%
OptionableNo Debt/Eq0.00 EPS Q/Q9.80% Profit Margin- Rel Volume1.74 Prev Close1.70
ShortableYes LT Debt/Eq0.00 EarningsFeb 13 AMC Payout- Avg Volume1.56M Price1.38
Recom2.00 SMA2024.82% SMA5048.40% SMA20057.86% Volume2,708,542 Change-18.82%
Jan-22-20 06:55AM  Should You Be Concerned About Daré Bioscience, Inc.'s (NASDAQ:DARE) Historical Volatility? Simply Wall St.
Jan-17-20 12:19PM  Analysts: 3 Healthcare Stocks That Could Gain 35% Or More TipRanks
Jan-15-20 08:00AM  Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update GlobeNewswire +13.39%
Jan-13-20 07:00AM  Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive Business Wire +96.92%
Dec-18-19 08:00AM  Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study GlobeNewswire
Dec-11-19 08:00AM  Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
Dec-10-19 08:00AM  Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems GlobeNewswire
Dec-09-19 07:15AM  DARE: Our Take On Ovaprene PCT Data, BV-1 Pivotal Study Design and Microchips Acquisition Zacks Small Cap Research
Dec-04-19 03:43PM  Edited Transcript of DARE earnings conference call or presentation 14-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-21-19 08:00AM  Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform GlobeNewswire
Nov-14-19 08:07AM  The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Benzinga
08:00AM  Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update GlobeNewswire
Nov-12-19 08:00AM  Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate GlobeNewswire -7.57%
Nov-11-19 08:00AM  Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform GlobeNewswire +8.06%
Nov-07-19 08:30AM  Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast GlobeNewswire
Oct-31-19 08:00AM  Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360 GlobeNewswire
Oct-28-19 08:00AM  Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference GlobeNewswire
Oct-24-19 08:00AM  Companies Like Daré Bioscience (NASDAQ:DARE) Can Be Considered Quite Risky Simply Wall St.
Oct-14-19 08:00AM  Daré Bioscience to Participate in Two Upcoming Investor Conferences GlobeNewswire +14.23%
Oct-10-19 08:00AM  Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo GlobeNewswire
Oct-07-19 08:00AM  Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference GlobeNewswire
Sep-13-19 02:04PM  Edited Transcript of DARE earnings conference call or presentation 14-Aug-19 8:30pm GMT Thomson Reuters StreetEvents +8.86%
Sep-11-19 08:00AM  Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics GlobeNewswire
Sep-09-19 12:13PM  Could The Daré Bioscience, Inc. (NASDAQ:DARE) Ownership Structure Tell Us Something Useful? Simply Wall St.
08:00AM  Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
Sep-04-19 08:00AM  Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Aug-14-19 04:01PM  Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update GlobeNewswire
Aug-12-19 01:59PM  Daré Bioscience Rallies On FDA Designation For Bacterial Vaginosis Drug Benzinga
08:00AM  Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis GlobeNewswire
Aug-08-19 08:00AM  Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology GlobeNewswire
Aug-06-19 08:00AM  Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast GlobeNewswire
Jul-22-19 08:00AM  Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition GlobeNewswire
Jul-17-19 08:00AM  Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model GlobeNewswire
Jul-15-19 08:00AM  Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors GlobeNewswire
Jul-11-19 03:51PM  The Daré Bioscience (NASDAQ:DARE) Share Price Is Down 35% So Some Shareholders Are Getting Worried Simply Wall St.
Jun-26-19 08:00AM  Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene® GlobeNewswire
Jun-17-19 08:00AM  Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
May-29-19 08:00AM  Daré Bioscience to Present at the 2019 BIO International Convention GlobeNewswire
May-28-19 03:00PM  DARE: Several Important Milestones, Including Ovaprene PCT Read-Out, Anticipated Later This Year Zacks Small Cap Research
11:22AM  Edited Transcript of DARE earnings conference call or presentation 14-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-14-19 04:00PM  Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update GlobeNewswire
May-08-19 08:00AM  Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research GlobeNewswire
May-07-19 08:00AM  Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast GlobeNewswire
Apr-15-19 10:26AM  Edited Transcript of DARE earnings conference call or presentation 4-Apr-19 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development GlobeNewswire
Apr-09-19 09:30AM  DARE: Pipeline Timelines Intact. Several Development-Related Milestones Upcoming Zacks Small Cap Research -22.71%
08:45AM  Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock GlobeNewswire
Apr-08-19 04:28PM  Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
08:00AM  Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences GlobeNewswire
Apr-01-19 04:30PM  Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq GlobeNewswire
08:00AM  Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast GlobeNewswire
Mar-29-19 08:00AM  World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board GlobeNewswire
Mar-18-19 02:00PM  Four Healthcare Stocks Heating Up On Monday ACCESSWIRE +128.26%
01:12PM  Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study MarketWatch
08:30AM  Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference GlobeNewswire
08:00AM  Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA GlobeNewswire
Mar-11-19 08:00AM  Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene® GlobeNewswire
Mar-05-19 08:00AM  Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference GlobeNewswire
Feb-28-19 08:00AM  Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference GlobeNewswire
Feb-05-19 08:00AM  Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-02-19 08:00AM  Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones GlobeNewswire
Dec-25-18 02:18PM  What Kind Of Investor Owns Most Of Daré Bioscience, Inc. (NASDAQ:DARE)? Simply Wall St.
Dec-19-18 04:33PM  Edited Transcript of DARE earnings conference call or presentation 13-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-17-18 03:45PM  DARE: DARE Adds Late-Stage Bacterial Vaginosis Candidate To Ever-Expanding Womens Health Pipeline Zacks Small Cap Research -15.94%
Dec-06-18 09:15AM  New Healthcare Trends Pushing Stocks Higher On Thursday ACCESSWIRE +15.16%
08:00AM  Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis GlobeNewswire
Dec-03-18 11:15AM  DARE: Ovaprene PCT Continues. TS Content Validity Study, Thermographic Study Underway Zacks Small Cap Research
Nov-29-18 08:00AM  Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
Nov-27-18 08:00AM  Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
Nov-13-18 07:30AM  Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results GlobeNewswire
Nov-06-18 08:00AM  Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire
Oct-30-18 08:00AM  Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C. GlobeNewswire
Oct-23-18 08:00AM  Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference GlobeNewswire
Oct-15-18 08:00AM  Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th 18th GlobeNewswire +17.68%
Oct-10-18 08:00AM  Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum GlobeNewswire
Sep-19-18 09:45AM  DARE: Upcoming Milestones Inc FDA Feedback on Topical Sildenafil FSAD Program Zacks Small Cap Research
Sep-17-18 08:00AM  Greg Matz Joins Daré Bioscience Board of Directors GlobeNewswire
Aug-30-18 08:00AM  Daré Bioscience, Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-02-18 08:00AM  Daré Bioscience, Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-23-18 08:10AM  Daré Bioscience, Growing Through Collaborations, Male Contraceptive, Analysts Target ACCESSWIRE
Jul-16-18 08:00AM  Daré Bioscience, Inc. Announces Asset Transfer Agreement with Hydra Biosciences, Inc. for CatSper Contraceptive Target GlobeNewswire +10.33%
Jun-18-18 07:20AM  Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks ACCESSWIRE
Jun-06-18 08:00AM  Daré Bioscience, Inc. Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer GlobeNewswire
Jun-05-18 07:30AM  DARE: Initiating Coverage of DARE With $6.75/share Price Target Zacks Small Cap Research
Jun-04-18 08:00AM  Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs GlobeNewswire
May-25-18 05:37PM  Daré Bioscience Inc (NASDAQ:DARE): When Will It Breakeven? Simply Wall St.
May-16-18 08:00AM  EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego GlobeNewswire
May-15-18 08:00AM  Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate GlobeNewswire
May-08-18 08:00AM  Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer GlobeNewswire -8.73%
May-07-18 08:00AM  Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients GlobeNewswire +10.59%
Apr-30-18 08:00AM  Daré Bioscience announces funding award to further the development of Ovaprene from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) GlobeNewswire +7.82%
Apr-26-18 08:10AM  Todays Research Reports on Stocks to Watch: Dare Bioscience and ACADIA ACCESSWIRE
Apr-25-18 08:00AM  Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals Intravaginal Ring (IVR) Technology Platform GlobeNewswire +56.69%
Apr-13-18 07:20AM  Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US ACCESSWIRE
Apr-11-18 08:00AM  Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors GlobeNewswire
Apr-02-18 04:05PM  Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update GlobeNewswire
12:15PM  Dare Bioscience, Inc. to Host Earnings Call ACCESSWIRE
Mar-29-18 08:30AM  Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018 GlobeNewswire
Mar-12-18 08:00AM  Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive GlobeNewswire
Mar-05-18 08:00AM  Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference GlobeNewswire
Dare Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy. The company has license agreement with ADVA-Tec, Inc. to develop and commercialize Ovaprene for human contraceptive use; and license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company is headquartered in San Diego, California.